“We are thankful to the amazing team at MHRA for the careful and expeditious consideration that led to clearance of our application,” said Dr. Wayne Holman, Co-Founder of Ridgeback
The pharma company has signed an agreement with the US National Institute of Allergy and Infectious Diseases (NIAID) to investigate baricitinib as an arm in the latter’s Adaptive
ARO-ENaC utilizes Arrowhead’s proprietary Targeted RNAi Molecule (TRiM) platform and is the company’s first inhaled RNAi candidate to target pulmonary epithelium. Chris Anzalone, Ph.D., president and chief executive
“In January of this year, we reported positive topline results from our PULSAR Phase 2 placebo-controlled trial of sotatercept in patients with PAH,” said Habib Dable, President and
In this connection, the RNAi therapeutics company completed the rolling submission of a new drug application (NDA) for lumasiran with the regulator. Considered to be an ultra-rare, life-threatening
CAR-T cell therapy represents a promising and future-defining shift in cancer treatment. Beam Therapeutics is developing a new generation of CAR-T product candidates using its proprietary base editing
The latest approval from the European Commission (EC) authorises ALUNBRIG to be used as a monotherapy for the treatment of adults having anaplastic lymphoma kinase-positive (ALK+) advanced non-small
In addition, the companies have completed a cross-license of their respective intellectual property for Alnylam’s lumasiran and Dicerna’s nedosiran investigational programs for the treatment of primary hyperoxaluria (PH).
The late-stage trial met both the co-primary endpoints, with Nucala added to standard of care delivering statistically significant improvements in the size of nasal polyps at week 52
BioArdis will retain all rights to the licensed product in the rest of the world. BIO-1262 is being evaluated as a potential new treatment for hepatocellular carcinoma (HCC)
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.